What You Should Know:
– Today, SiPhox Health, a Burlington, MA-based company building the next generation of lab-grade home health testing with silicon photonics raises $27M in funding, including a $10M Seed led by Khosla Ventures and Y Combinator, and a $17M Series A led by Intel Capital.
– The SiPhox Home and Health testing systems offer innovative and efficient blood collection solutions for consumers, healthcare systems, pharmaceutical companies, and research teams focusing on longevity and chronic disease management.
At-Home Testing Kit Measuring 17 Biomarkers
Today, 6 out of 10 Americans are living with a chronic disease, and while access to low-cost, convenient testing could help prevent and manage these conditions, the tests are expensive, time-consuming and burdensome. That’s why SiPhox Health is shifting the focus from treatment to prevention – making individualized testing accessible at scale by enabling at-home testing of biomarkers via silicon photonic sensors.
Currently, SiPhox Health provides a mail-in blood collection kit that measures 17 biomarkers for inflammation, metabolic, hormonal and cardiovascular health. The funding will enable team expansion as SiPhox Health works towards FDA clearance for its SiPhox Home platform, which will offer a broad menu of proteins and hormone tests from a finger prick blood sample, with results in five minutes or less.
“SiPhox’s goal is to create category-defining health tracking products starting with the SiPhox Home, which is a 100-fold improvement over existing blood diagnostics. Eventually, our technology will enable the ultimate wearable device for measuring proteins, hormones, and small molecules continuously,” said Michael Dubrovsky, SiPhox Health co-founder and Chief Product Officer. “Every cell in the human body is a much more advanced sensor than anything on the market today, showing we are nowhere near the physical limits for performance and miniaturization in diagnostics.”